AR068988A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
AR068988A1
AR068988A1 ARP080104473A ARP080104473A AR068988A1 AR 068988 A1 AR068988 A1 AR 068988A1 AR P080104473 A ARP080104473 A AR P080104473A AR P080104473 A ARP080104473 A AR P080104473A AR 068988 A1 AR068988 A1 AR 068988A1
Authority
AR
Argentina
Prior art keywords
methyl
aqueous pharmaceutical
pharmaceutical composition
oxy
composition according
Prior art date
Application number
ARP080104473A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR068988A1 publication Critical patent/AR068988A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente proporciona composiciones acuosas farmacéuticas que comprenden un compuesto que es 4-[(4-clorofenil)metil]-2-({(2R)-1-[4-(4-{[3-(hexahidro-1H-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2H)-ftalazinona, de fórmula (1), o una sal suya farmacéuticamente aceptable, y su uso en el tratamiento de diversas enfermedades inflamatorias y/o alérgicas tales como rinitis alérgica. Reivindicación 2: Una composición farmacéutica acuosa que comprende (i) un compuesto que es 4-[(4-clorofenil)metil]-2-({(2R)-1-[4-(4-{[3-(hexahidro-1H-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2H)-ftalazinona, de fórmula (1), o una sal del mismo farmacéuticamente aceptable; y (ii) un compuesto que es éster S-fluorometílico de ácido 6a,9a-difluoro-17a-[(2-furanilcarbonil)oxi]-11b-hidroxi-16a-metil-3-oxo-androsta-1,4-dien-17b-carbotioico (furoato de fluticasona), de fórmula (2), o un solvato suyo. Reivindicación 7: Una composición farmacéutica acuosa de acuerdo con una cualquiera de las reivindicaciones 1 a 6, que comprende además: a) un agente suspensor; b) un agente de conservación; c) un agente humectante; y d) un agente regulador de la isotonicidad. Reivindicación 8: Una composición farmacéutica acuosa de acuerdo con la reivindicación 7, que comprende además un co-disolvente. Reivindicación 29: Una composición farmacéutica acuosa de acuerdo con una cualquiera de las reivindicaciones 1 a 28, que comprende la sal 1,5-naftalenodisulfonato de 4-[(4-clorofenil)metil]-2-({(2R)-1-[4-(4-{[3-(hexahidro-1H-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2H)-ftalazinona, monohidrato. Reivindicación 30: Una composición farmacéutica acuosa de acuerdo con una cualquiera de las reivindicaciones 2 a 28, que comprende furoato de fluticasona en forma no solvatada.
ARP080104473A 2007-10-16 2008-10-14 Composiciones farmaceuticas AR068988A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98022607P 2007-10-16 2007-10-16
US5723008P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
AR068988A1 true AR068988A1 (es) 2009-12-23

Family

ID=40198721

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104473A AR068988A1 (es) 2007-10-16 2008-10-14 Composiciones farmaceuticas

Country Status (6)

Country Link
AR (1) AR068988A1 (es)
CL (1) CL2008003036A1 (es)
PE (1) PE20091089A1 (es)
TW (1) TW200932243A (es)
UY (1) UY31400A1 (es)
WO (1) WO2009050159A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811447D0 (en) * 2008-06-20 2008-07-30 Glaxo Group Ltd Formulations
CN104869980A (zh) * 2012-12-17 2015-08-26 葛兰素集团有限公司 用于治疗炎症性病症和/或变应性病症的左卡巴斯汀和糠酸氟替卡松的组合
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
MX2008013406A (es) * 2006-04-20 2008-11-04 Glaxo Group Ltd Derivados de 4-bencilftalazinona 2-sustituida como antagonistas de la histamina h1 y h3.

Also Published As

Publication number Publication date
WO2009050159A1 (en) 2009-04-23
PE20091089A1 (es) 2009-08-24
CL2008003036A1 (es) 2009-05-08
TW200932243A (en) 2009-08-01
UY31400A1 (es) 2009-05-29

Similar Documents

Publication Publication Date Title
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
UY29840A1 (es) Compuestos de pirimidina amida como inhibidores de pgds
LTC1755590I2 (lt) Glikopirolato ir beta2 adrenoceptoriaus agonisto derinys
CR9003A (es) 2,6 sustituido-4-monosustituido amino-pirimidinas como antagonistas del repector de prostaglandina d2
CR8918A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38
AR061134A1 (es) Derivados de tioxantina
PE20091386A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
PE20220761A1 (es) Inhibidores de dihidroorotato deshidrogenasa
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
NZ600840A (en) Indole compound and pharmaceutical use thereof
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
AR054411A1 (es) Combinacion farmaceutica que comprende un compuesto olefinico de 8- azoniabiciclo [ 3.2.1] octano y uno o mas ingredientes terapeuticos distintos, composicion farmaceutica que la comprende y uso de dichos componentes para prepararla
PE20071092A1 (es) Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
AR068988A1 (es) Composiciones farmaceuticas
WO2007025880A3 (en) Pyrazolone derivatives as 11-beta hsd1 inhibitors
GT200800058A (es) Diarilurea para el tratamiento de hipertensión pulmonar
AR038213A1 (es) Esteres hidroxamato del acido n-(4-fenil sustituido)-antranilico
AR066077A1 (es) Tiadiazoliloxifenilamidinas y su uso como fungicidas
PA8628901A1 (es) Derivados de 4-alquil-y 4-alcanoil-piperidina sustituidos y su uso como antagonistas de neuroquininas
CL2011002461A1 (es) Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica.
EA201100368A1 (ru) Амидные соединения, полезные в терапии
NZ620074A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal